At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 10 target
Drug / intervention
CAR-T cellsbiological
Likely dose
Not stated in record
Key inclusion· 6
- ✓Ages 8-75 years
- ✓Chronic (>12 months) or refractory ITP
- ✓Platelet count <30 x 10^9/L
- ✓No other disease causing thrombocytopenia besides ITP
Key exclusion· 19
- ✕Secondary immune thrombocytopenia
- ✕Preventive splenectomy
- ✕Other hemostatic disorders
- ✕Antiplatelet or anticoagulant drugs >3 consecutive days within 2 weeks of study start
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT06352281Phase 2RecruitingMonitorUpdated 23mo ago · Completion was 5mo agoSlow Enrollment
Monitor
An Investigator-initiated Trial to Evaluate the Efficacy and Safety of CAR-T Cells Therapy in the Treatment of Chronic or Refractory Primary Immune Thrombocytopenia (ITP)
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China·interventional·Posted Apr 8, 2024·Updated Jul 22, 2024
In Brief
A Phase 2 clinical trial evaluating CAR-T cells for ITP - Immune Thrombocytopenia. Currently recruiting, targeting 10 participants across 1 site.
Signals
Enrolling slower than its timeline implies
Detailed Summary
It is a single-center, single-arm, open-labeled clinical trial to evaluate the efficacy and safety of CAR-T cells therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsITP - Immune Thrombocytopenia
CountriesChina
Collaborators--
Timeline
Phase 2Recruiting
20242025202620272028
Enrollment StartFeb 2024
First PostedApr 2024
Primary CompletionJan 2026
TodayJul 2026
Study CompletionDec 2027
First PostedApr 8, 2024
Enrollment StartFeb 1, 2024
Primary CompletionJan 1, 2026
Study CompletionDec 31, 2027
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 2.2 years ago
Interventions
CAR-T cellsbiological
CAR-T cells will be administered by vein. Before CAR-T infusion，patients will get a 3-5 days lymphodepletion therapy with fludarabine and cyclophosphamide.